Compared to Dupilumab Upadacitinib rapidly improves itching and clears skin in atopic dermatitis: JAMA Dr Manoj Kumar Nayak9 Aug 2021 3:30 AM GMTUpadacitinib vs Dupilumab in adult atopic dermatitis (AD) : JAMA studyAtopic dermatitis is a severely pruritic relapsing disorder with multiple...
Dupilumab significantly improves itch and hives in chronic spontaneous urticaria patients: Study Hina Zahid5 Aug 2021 3:30 AM GMTUSA: Adding Dupixent (dupilumab) to standard-of-care antihistamines significantly reduced itch and hives in patients with moderate-to-severe chronic...
Dupilumab may Raise Risk of Ocular Disease in Atopic Dermatitis Patients: Study Josepha James8 Jun 2021 3:45 AM GMTDupilumab is the first human monoclonal antibody approved for the treatment of atopic dermatitis (AD). However, a recent study suggests that the use...
Dupilumab helps reduce exacerbations in kids with moderate-to-severe asthma: VOYAGE trial Hina Zahid29 May 2021 3:30 AM GMTNew York, NY: Dupilumab (Dupixent) significantly reduced exacerbations in patients aged 6 to <12 years with uncontrolled, moderate-to-severe...
Eczema Treatment linked with Development of Conjunctivitis, reveals study MD Bureau26 May 2021 3:30 AM GMTAtopic dermatitis (AD) is a common, chronic, inflammatory skin condition that affects up to 25% of children and 5% of adults worldwide. In a recent...
Sanofi wins EU approval for Dupixent for atopic dermatitis in children ruchika1 Dec 2020 7:20 AM GMTDupixent is the only systemic medicine approved in the EU to treat these patients.
Dupilumab reduces severe attacks in asthmatic children, finds study Medha14 Oct 2020 3:48 PM GMTDelhi: Dupilumab (Dupixent) significantly reduces severe asthma attacks in children with moderate-to-severe asthma, finds a recent study.The...
Sanofi Dupixent gets USFDA Breakthrough Therapy designation to treat eosinophilic esophagitis ruchika16 Sep 2020 8:21 AM GMTParis: Drug major, Sanofi has recently secured Breakthrough Therapy designation from the U.S. Food and Drug Administration(USFDA) for its Dupixent ( du...
Dupilumab receives FDA's Breakthrough Therapy Status for eosinophilic esophagitis Medha16 Sep 2020 2:16 AM GMTUSA: Dupilumab (Dupixent) has received the US FDA's Breakthrough Therapy designation for the treatment of eosinophilic esophagitis (EoE) in patients...
Sanofi-Regeneron Dupixent gets NMPA nod to treat atopic dermatitis ruchika22 Jun 2020 5:00 AM GMTThe approval was based on positive data from the global LIBERTY AD clinical trial program that included nearly 3,000 patients with inadequately...
Sanofi to present growth opportunities, development strategy for Dupixent in type 2 inflammatory diseases ruchika14 Jun 2020 3:45 AM GMTAs announced in December 2019, Sanofi expects to deliver strong growth for Dupixent with the ambition of achieving more than €10 billion in peak sales ...
Dupixent met co-primary endpoints in Part A of Phase 3 trial: Regeneron, Sanofi ruchika25 May 2020 11:55 AM GMTDupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins.
